Amylyx Pharmaceuticals faces a class-action lawsuit over its ALS drug, Relyvrio, alleging overstated commercial prospects and stock price drop.
Amylyx Pharmaceuticals faces a class-action lawsuit over its ALS drug, Relyvrio, which allegedly overstated commercial prospects, led to patients discontinuing treatment after six months, and showed a decreasing rate of new patients starting treatment. The lawsuit comes after the company's announcement of a third-quarter financial results miss and a 31.89% stock price drop. Investors have until April 4, 2024, to apply to the court as the lead plaintiff in the lawsuit.
March 11, 2024
9 Articles